NEW YORK, November 9, 2017 —
According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016 to 2022. Cancer immunotherapy is provided to cancer patients to stop or slow down the spread of cancer cells, as well as improve the body's immune system to fight off cancer cells. The sector is expected to grow due to the growing number of cancer patients, technological advancements, effectiveness of treatments, and the increasing demand for treatments. Cancer immunotherapy treats many of the most common and fatal cancers, but most companies focus on a specific type. Regen Biopharma, Inc. (OTC: RGBP), Endocyte, Inc. (NASDAQ: ECYT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), CASI Pharmaceuticals Inc. (NASDAQ: CASI), ArQule, Inc. (NASDAQ: ARQL)
A technology category that is projected to be the biggest market driver for this sector is Monoclonal antibodies, which is a category in cancer immunotherapy. These antibodies will treat a variety of cancers such as breast cancer, lung cancer, and colorectal cancer. Research from the National Cancer Institute showed that 14.5 million were diagnosed with cancer, and is expected to reach 19 million by 2024.
Regen Biopharma, Inc. (OTCQB: RGBP) just announced breaking news after the market close yesterday that, “recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and specific towards the NR2F6 target.
These two programs are integrally linked. Success in determining the structure of NR2F6 will inform future work on medicinal chemistry, as well as confirm the exact nature of the interaction between Regen's small molecules and NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and Lupus.
“The object of the three-dimensional x-ray structure program is to shed light on exactly how our small molecules bind to and modulate NR2F6 activity. Imagine the NR2F6 nuclear receptor (protein) has a specific pocket where activators bind. We don't know the shape of that pocket, although we are beginning to infer it from the key structural elements of our small molecules that bind and activate it. With the actual structural data in hand from the three-dimensional x-ray structure, we will be able to see nuances that will both explain our success so far and will guide us as we make more small molecules. This will also help us improve on the small molecules we have made so far,” said Harry Lander, President and Chief Scientific Officer of Regen BioPharma Inc.
“The three-dimensional x-ray structure program, coupled with our medicinal chemistry program will enhance Regen's drug development process. These two programs linked together will give us a much clearer picture of what is actually happening at the molecular level,” said David Koos, Ph.D., Chairman and CEO of Regen BioPharma Inc. “That, in turn, will help any of our potential co-development partners feel more comfortable with our mechanism of action.”
About Regen BioPharma Inc.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is targeting the immunotherapy space, seeking to rapidly advance small molecule immunological therapies to treat cancer and autoimmunity through pre-clinical and Phase I/II clinical trials. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com .
Endocyte, Inc. (NASDAQ: ECYT) is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. On October 02, 2017, the company announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. Endocyteintends to move quickly into Phase 3 development of 177Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer. 177Lu-PSMA-617 delivers the short-range beta-emitting radioactive isotope lutetium (177Lu) selectively to tumor cells while by-passing non-PSMA-expressing healthy cells with encouraging efficacy and safety results. As highlighted in roughly 20 peer reviewed publications of studies in the post-chemotherapy compassionate use setting, 177Lu-PSMA-617 has consistently demonstrated a PSA response (defined as greater than 50% decline from baseline) in 40% to 60% of patients, and a RECIST response rate in soft tissue disease of between 40% and 50%.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company's pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. On August 23, 2017, the company announced that patient enrollment has been completed in the Company's Phase 2b METRIC study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that overexpress gpNMB. Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer. Overexpression of gpNMB has been shown to promote the migration, invasion and metastasis of the disease. It is highly expressed in triple negative breast cancers, where it is associated with increased risk of recurrence and poor clinical outcome.
CASI Pharmaceuticals Inc. (NASDAQ: CASI) is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. On September 7, 2017, the company provided an update to its pipeline. China's Food and Drug Administration (CFDA) has granted priority review for CASI's import drug registration clinical trial application for EVOMELA (melphalan) for Injection. The CFDA review of CASI's MARQIBO import drug clinical trial application (CTA) is in process.
ArQule, Inc. (NASDAQ: ARQL) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of its patients. The company's clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule's proprietary pipeline includes: Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), as well as in multiple oncology indications; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. “The Latest Buzz in Financial News”
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: [email protected] , +1-877-601-1879
Latest posts by Brad Bennett (see all)
- MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California - February 18, 2018
- Mario Lopez Announced As Host To The 'Splash of Love' Gala Fundraiser At Proud Bird Food Bazaar & Events Center - February 18, 2018
- Oxnard Teen, Skilled Boxer Honored as BGCOP's Youth of the Year - February 18, 2018